



## BEXIMCO PHARMACEUTICALS LTD.

2<sup>nd</sup> May, 2006

### Results for the year ended 31 December 2005

Beximco Pharmaceuticals Limited (AIM Symbol: BXP) today announces its results for the year ended 31 December 2005.

#### Highlights

##### Products

- 49 products launched across a range of therapeutic classes
- 55 new product registrations in export markets
- Sri Lanka has become a new export market

##### Corporate

- Successfully integrated Beximco Infusions Limited
- Successfully placed £12 million and admitted GDRs to trading on AIM in October 2005
- Completed construction of new Oral Solid Dosage (OSD) plant built to USFDA standards and two out of five new OSD lines are currently being installed
- Commenced conversion of Metered Dose Inhaler (MDI) plant to manufacture HFA inhalers with the technical collaboration of Bepak Europe. Conversion is scheduled to be completed during Q3 2006

##### Financial\*

- Net Sales increased by 38% to over Tk.3,327.0m (£26.5m) (20% increase on a pro-forma basis)
- Profit before tax\*\* increased by 37.9% to Tk.509.6m (£4.1m) (21.4% increase on a pro-forma basis)
- EPS increased by 35% to Tk. 6.36 (5.1p)
- Cash dividend of 15% (gross) of par value (representing Tk.1.5, or 1.2p per share) declared with record date of 1 June 2006, and payment date on or before 21 August 2006.

##### Post year end highlights

- Introduced Oseflu® (Oseltamivir) to the Bangladesh market which aims to combat the growing threat of Bird Flu
- Launched 14 new products in the first quarter of 2006
- Signed agreement with a leading Indian API manufacturer to set up an API plant for Ranitidine, Ciprofloxacin & Omeprazole
- Commenced manufacturing of Penicillin API

The AGM will be held on 22 June 2006 at 10.30 a.m. at 1 Shahbag C/A, Dhaka, Bangladesh

Nazmul Hassan, CEO of Beximco pharmaceuticals, commented:

“Beximco Pharmaceuticals has had an extremely good year, and the successful flotation on AIM has enabled us to progress our strategic plans.

“We have continued our growth into 2006, and have already successfully launched 14 new products, most significantly the introduction of our generic bird flu drug, Oseflu™ into the

Bangladeshi market. We believe that Beximco Pharma has a strong platform to continue to grow profitably in both the domestic and international markets.”

The full audited accounts are available from the Company’s website: [www.beximcopharma.com](http://www.beximcopharma.com)

*\* Financial figures on a pro-forma basis include the result of BPL and Beximco Infusions Limited which was effectively integrated into BPL from 1 July 2005*

*\*\* Profit before tax and contribution to Workers’ Profit Participation Fund  
Exchange rate used: £1=Tk.125.35*

**For further enquiries please contact:**

**Beximco Pharma**

Nazmul Hassan, CEO

Tel: +880 2 861 9151, ext.2080

**Libertas Capital**

Aamir Quraishi/Charles Goodfellow

Tel: +44 (0)20 7569 9650

**Financial Dynamics**

David Yates / John Gilbert

Tel: +44 (0)20 7269 7169

**Notes to Editors**

**About Beximco Pharmaceuticals Limited**

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also undertakes contract manufacturing for GlaxoSmithKline and is about to commence manufacturing for Novartis. The Company operates from a 20 acre site in Dhaka and currently employs over 1800 staff.

The Company’s products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Pakistan, Nepal and Myanmar and in other markets overseas, principally in East Africa (including Kenya) and South East Asia (including Singapore).

END